SVA Archives - BioTuesdays

Executive Moves

Sernova appoints David Patterson Ph.D. to BOD

Sernova Corp. (TSX:SVA) has announced the appointment of David Patterson, Ph.D., to its board of directors, effective immediately. “I am pleased to have been able to attract David Paterson’s significant talent to...

September 19, 2024

Executive Moves

Sernova appoints Jonathan Rigby as executive chairman

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) has named Jonathan Rigby as executive chairman, effective immediately. Mr. Rigby, previously a director with the company, replaces chairman Brett Whalen, who has resigned...

July 18, 2024

Executive Moves

Sernova names Cynthia Pussinen as CEO

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...

September 5, 2023

Executive Moves

Sernova names Frank Shannon as VP clinical development, regulatory affairs

Frank Shannon Sernova (TSXV:SVA; OTC:SEOVF; FSE/XETRA:PSH) appointed 25-year pharmaceutical industry executive, Frank Shannon, as VP of clinical development and regulatory Affairs. Mr. Shannon most recently served...

June 30, 2021

Developments

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...

January 15, 2021

Feature

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...

January 5, 2021

Markets

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

Leede Jones Gable launched coverage of Sernova (TSXV:SVA) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock was quoted at 44 cents in early trading on Dec. 15. “We are positive on the...

December 15, 2020

Tag - SVA

Sernova appoints David Patterson Ph.D. to BOD

Sernova appoints Jonathan Rigby as executive chairman

Sernova names Cynthia Pussinen as CEO

Sernova names Frank Shannon as VP clinical development, regulatory affairs

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

General

More